HealthLinx and CytogenDx to Develop New Ovarian Cancer IVD for China
September 12, 2011 at 07:11 AM EDT
HealthLinx, an Australian IVD company, has struck a deal with China CRO CytogenDx to seek SFDA approval for OvPlex, a HealthLinx clinical-stage diagnostic test for ovarian cancer. OvPlex measures plasma levels of anterior gradient protein 2 (AGR2), a new ovarian cancer biomarker. In a recent test, OvPlex was more accurate than CA125, the current IVD tool for ovarian cancer. More details.... Stock Symbol: (ASK: HTX) Share this with colleagues: